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Question 3
Answer: b The initial dose is guanfacine 1mg daily, given either in the morning or the evening, titrated according to response in increments of not more than 1mg a week to a maximum of 4mg daily in children 6-12 years and up to 7mg daily, depending on body weight, in adolescents 13-17 years, corresponding to a usual dose range of 0.05-0.12mg/kg/day. 
Question 2
Answer: e. The summary of product characteristics (SPC) states that before starting treatment with guanfacine, a baseline evaluation is required to identify patients at increased risk of QT-prolongationrelated arrhythmia, hypotension, bradycardia, somnolence, sedation and weight gain. This should include assessment of cardiovascular status (including blood pressure and heart rate), concomitant medications, past and present medical and psychiatric disorders or symptoms, family history of sudden cardiac/unexplained death and pretreatment height and weight. 
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Question 5
Two phase III flexible-dose double-blind studies compared guanfacine (dose range 1-7mg/day) with placebo using the change in ADHD-RS-IV from baseline as the primary outcome. What was placebo-adjusted mean difference in score for both studies? 
Question 4
Answer: c. In one study involving 314 adolescents (minimum ADHD-RS-IV score of 32 at baseline) the mean decrease in ADHD-RS-IV from baseline was -24.6 with guanfacine compared with -18.5 for placebo (placebo-adjusted mean difference -6.1; effect size 0.52; p<0.001) after 13 weeks. In the other study of 338 children and adolescents, the mean change in ADHD-RS-IV total score (from a baseline of 43) was -23.9 for guanfacine and -15.0 for placebo (placebo-adjusted mean difference of -8.9 [p<0.001]).
